Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.42 |
| ▸ | GSR | P00390 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857246 | 1.00 | — | — | |
| SCHEMBL371486 | 1.00 | CA1 (0.53) | CA1CA2CA4TSHRSLC18A3 | |
| SCHEMBL3339455 | 1.00 | CA1 (0.53) | CA1CA2CA4TSHRSLC18A3 | |
| SCHEMBL1849613 | 1.00 | CA1 (0.53) | CA1CA2CA4TSHRSLC18A3 | |
| SCHEMBL740271 | 1.00 | — | — | |
| SCHEMBL560334 | 1.00 | CA1 (0.53) | CA1CA2CA4TSHRSLC18A3 | |
| SCHEMBL765400 | 1.00 | — | — | |
| SCHEMBL3339811 | 1.00 | — | — | |
| SCHEMBL13894718 | 1.00 | CA1 (0.53) | CA1CA2CA4TSHRSLC18A3 | |
| SCHEMBL1773898 | 1.00 | CA1 (0.53) | CA1CA2CA4TSHRSLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838677-B2 | Processes for preparing morphinans and intermediates thereof | MALLINCKRODT INC (US) | 2010-11-23 | — | — | US | claimed |
| EP-2199285-A1 | Processes for preparing morphinans and intermediates thereof | Mallinckrodt Inc. (US) | 2010-06-23 | — | — | EP | claimed |
| US-20080262231-A1 | Processes for Preparing Morphinans and Intermediates Thereof | LIEBEL-FLARSHEIM COMPANY LLC | 2008-10-23 | — | — | US | claimed |
| EP-1861373-A2 | PROCESSES FOR PREPARING MORPHINANS AND INTERMEDIATES THEREOF | MALLINCKRODT, INC. (US) | 2007-12-05 | — | — | EP | claimed |
| WO-2006098855-A2 | PROCESSES FOR PREPARING MORPHINANS AND INTERMEDIATES THEREOF | MALLINCKRODT INC. (US) | 2006-09-21 | — | — | WO | claimed |
| EP-3433086-B1 | ENERGETIC MATERIALS | TNO (NL) | 2026-05-06 | — | — | EP | disclosed |
| US-12516000-B2 | Energetic materials | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2026-01-06 | — | — | US | disclosed |
| EP-3917445-B1 | METHODS OF MAKING AND POSTPROCESSING ORTHODONTIC ARTICLES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-2868692-B2 | Stabilized matrix-filled liquid radiation curable resin compositions for additive fabrication | STRATASYS INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12296528-B2 | Compositions and articles for additive fabrication and methods of using the same in particle image velocimetry testing | STRATASYS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12269933-B2 | Stabilized matrix-filled liquid radiation curable resin compositions for additive fabrication | STRATASYS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4491679-A2 | STABILIZED MATRIX-FILLED LIQUID RADIATION CURABLE RESIN COMPOSITIONS FOR ADDITIVE FABRICATION | Stratasys, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| WO-2000003300-A1 | STEREOLITHOGRAPHIC COMPOSITION FOR PREPARING POLYETHYLENE-LIKE ARTICLES | DSM N.V. (NL) | 2000-01-20 | — | — | WO | disclosed |
| EP-0964004-A1 | New metallocene catalyst for olefin or styrene polymerization and polymerization method using the metallocene catalyst | Samsung General Chemicals Co., Ltd. (KR) | 1999-12-15 | — | — | EP | disclosed |
| EP-0686660-A1 | Sound absorbing and decoupling syntactic foam | WESTINGHOUSE ELECTRIC CORPORATION (US) | 1995-12-13 | — | — | EP | disclosed |
| US-5422380-A | A syntactic open hollow addition-condensation polyurethane copolymer comprising expanded polystyrene microspheres; acoustic distortion; underwater vehicles | WESTINGHOUSE ELECTRIC CORPORATION (US) | 1995-06-06 | — | — | US | disclosed |
| US-5154738-A | Passing mixture through gas chromatography column having dialkyl trifluoroacyl ether derivative of cyclodextrin, eluting separated compounds | ADVANCED SEPARATION TECHNOLOGIES, INC. (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0467978-A4 | THE USE OF FLUID INSOLUBLE OXIDIZING AGENTS TO ELIMINATE INTERFERING SUBSTANCES IN OXIDATION-REDUCTION MEASURING SYSTEMS | — | 1992-03-11 | — | — | EP | disclosed |
| EP-0467978-A1 | THE USE OF FLUID INSOLUBLE OXIDIZING AGENTS TO ELIMINATE INTERFERING SUBSTANCES IN OXIDATION-REDUCTION MEASURING SYSTEMS | ENZYMATICS, INC. (US) | 1992-01-29 | — | — | EP | disclosed |
| WO-1990012113-A1 | THE USE OF FLUID INSOLUBLE OXIDIZING AGENTS TO ELIMINATE INTERFERING SUBSTANCES IN OXIDATION-REDUCTION MEASURING SYSTEMS | ENZYMATICS, INC. (US) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262231-A1 | Processes for Preparing Morphinans and Intermediates Thereof | NME2, NISCH, NME1 | CA1 394/4885CA2 395/4885CA4 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.